Sirolimus: Clinical Trials

249 trials of Sirolimus, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

137 completed, 30 terminated, 27 recruiting, 20 active not recruiting. 249 Phase 1, 106 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1249Completed 137, Terminated 30, Recruiting 27, Active not recruiting 20, Withdrawn 16, Unknown 12, Not yet recruiting 5, Enrolling by invitation 1, Suspended 1
Phase 2106Completed 45, Recruiting 17, Terminated 12, Active not recruiting 11, Unknown 8, Withdrawn 7, Not yet recruiting 4, Enrolling by invitation 1, Suspended 1

Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus

Trials (filtered) newest first · largest first

All 249 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH)
Phase 1 / Phase 2Not yet recruitingMassachusetts General Hospital152027-01-012026-06-25
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
Sirolimus (rapamycin), Placebo - Genetic Predisposition to Disease, Healthy Volunteer
Phase 1RecruitingUniversity of Missouri-Columbia2252026-12-012026-10-05
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)542026-11-232026-11-18
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4
Phase 1 / Phase 2Not yet recruitingCedars-Sinai Medical Center602026-11-012026-09-16
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin
Phase 1 / Phase 2RecruitingUmoja Biopharma2742026-11-012026-11-10
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM)
Phase 1RecruitingUmoja Biopharma1002026-11-012026-11-13
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Familial Platelet Disorder With Associated Myeloid Malignancy
Phase 1RecruitingOHSU Knight Cancer Institute62026-10-052026-10-13
Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors.
Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer
Phase 1 / Phase 2Not yet recruitingUniversity Hospital, Strasbourg, France892026-10-012026-10-01
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes
Phase 1 / Phase 2Not yet recruitingPeking University People's Hospital402026-10-012026-09-09
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
Domatinostat, Sirolimus - Sarcoma, Osteosarcoma
Phase 1 / Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute742026-07-152026-09-03
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Sirolimus, Teclistamab, Talquetamb - Multiple Myeloma
Phase 1RecruitingChristopher Strouse102026-06-012026-06-04
MTOR Inhibitors in Older Adults
Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging
Phase 1 / Phase 2RecruitingUniversity of Texas Southwestern Medical Center602026-05-112026-06-25
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
ASP2957, Methylprednisolone, Prednisolone - X-Linked Myotubular Myopathy
Phase 1 / Phase 2RecruitingAstellas Gene Therapies92025-12-152026-11-09
Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus
Sirolimus, Busulfan, Horse -Anti-thymocyte - Severe Combined Immune Deficiency (SCID)
Phase 1 / Phase 2WithdrawnNational Institute of Allergy and Infectious Diseases (NIAID)2025-11-262025-12-01
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms
Phase 1RecruitingNational Cancer Institute (NCI)1552025-11-142026-10-16
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
sirolimus (albumin-bound), DP303c, SYS6043 - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.4442025-11-132025-11-28
Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome
Urbagen gene addition therapy, Sirolimus, Methylprednisolone (Corticosteroid) - CTNNB1 Neurodevelopmental Syndrome
Phase 1 / Phase 2RecruitingCTNNB1 Foundation122025-11-012026-03-25
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD)
Phase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)102025-09-102026-09-08
A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
lamivudine, rapamycin, Exercise Regimen - Smokers, Former Smokers
Phase 1Active not recruitingIcahn School of Medicine at Mount Sinai202025-08-122026-08-27
Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study
Base-edited hematopoietic stem and progenitor cells, Alemtuzumab, Sirolimus - CD40L-HyperIgM Syndrome
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)12025-07-162026-07-31

Showing 20 of 249. Sign in to see all of them.

Conditions studied

Graft vs Host Disease (21)  ·  Multiple Myeloma (19)  ·  Myelodysplastic Syndromes (14)  ·  Lymphoma (13)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (13)  ·  Hematologic Neoplasms (12)  ·  Leukemia (12)  ·  Lymphoma, Non-Hodgkin (12)  ·  Anemia, Sickle Cell (11)  ·  Carcinoma, Non-Small-Cell Lung (11)  ·  Hodgkin Disease (11)  ·  Leukemia, Myeloid, Acute (10)  ·  Prostatic Neoplasms (10)  ·  Breast Neoplasms (9)  ·  Glioblastoma (9)

Sponsors

National Cancer Institute (NCI) (37)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (12)  ·  M.D. Anderson Cancer Center (11)  ·  Mayo Clinic (9)  ·  City of Hope Medical Center (7)  ·  University of Chicago (7)  ·  CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (5)  ·  National Eye Institute (NEI) (5)  ·  National Heart, Lung, and Blood Institute (NHLBI) (5)  ·  Roswell Park Cancer Institute (5)  ·  H. Lee Moffitt Cancer Center and Research Institute (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  Yale University (4)  ·  Children's Hospital of Philadelphia (3)  ·  Emory University (3)

Countries

United States (201)  ·  China (12)  ·  Canada (10)  ·  Spain (5)  ·  Australia (3)  ·  France (3)  ·  Italy (3)  ·  Germany (2)  ·  India (2)  ·  Netherlands (2)  ·  Sweden (2)  ·  Israel (1)  ·  Japan (1)  ·  Russia (1)  ·  Singapore (1)

Top investigators

Christopher G Kanakry, M.D. (5)  ·  Elizabeth M Kang, M.D. (5)  ·  Ezra Cohen, MD (3)  ·  Filip Janku, MD, PHD (3)  ·  Kunle Odunsi (3)  ·  Luke Walker, MD (3)  ·  Ai-Ling Lin, PhD (2)  ·  Amit Oza (2)  ·  Courtney F Joseph, M.D. (2)  ·  Haris Ali (2)  ·  John F Tisdale, M.D. (2)  ·  Jose-Antonio Perez-Simon, MD-PhD (2)  ·  Mandeep Singh, MD (2)  ·  Robert Montgomery (2)

Results publications

PMID 36240296, PMID 42133908, PMID 40132910, PMID 41871072, PMID 10028970, PMID 10030657, PMID 10199738, PMID 10213344, PMID 10556226, PMID 10594802, PMID 10598732, PMID 10802712, PMID 10830164, PMID 10952828, PMID 11055975, PMID 11057898, PMID 11250334, PMID 11514367, PMID 11803349, PMID 12088775, PMID 12555153, PMID 12652219, PMID 12668503, PMID 12714020, PMID 12738602, PMID 12742978, PMID 12906982, PMID 12962864, PMID 1423934, PMID 14612424, PMID 14757690, PMID 14996650, PMID 15226426, PMID 15239621, PMID 15302787, PMID 15543153, PMID 15557389, PMID 16030064, PMID 16199143, PMID 16297769, PMID 16297770, PMID 16297806, PMID 16364861, PMID 16611334, PMID 16614412, PMID 16642009, PMID 16795076, PMID 16873412, PMID 16896165, PMID 17060862

NIH funding

P30CA016672 (5), P30CA008748 (3), P30CA015083 (3), U01CA069856 (3), U01CA097452 (3), U10CA025224 (3), 2009 (2), 2025 (2), N01CM00071 (2), N01CM62201 (2), P30CA006973 (2), P30CA015704 (2), P30CA016056 (2), P30CA033572 (2), P30CA069533 (2)